Adage Capital Partners Portfolio holdings
AUM
$59.3B
1-Year Return
26.26%
This Quarter Return
-1.77%
1 Year Return
+26.26%
3 Year Return
+130.73%
5 Year Return
+248.99%
10 Year Return
+658.76%
AUM
$54B
AUM Growth
-$3.22B
(-5.6%)
Cap. Flow
-$953M
Cap. Flow
% of AUM
-1.77%
Top 10 Holdings %
Top 10 Hldgs %
28.72%
Holding
985
New
115
Increased
314
Reduced
359
Closed
149
Top Buys
| 1 |
Hubbell
HUBB
|
+$208M |
| 2 |
Norfolk Southern
NSC
|
+$145M |
| 3 |
Insmed
INSM
|
+$137M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$136M |
| 5 |
Soleno Therapeutics
SLNO
|
+$116M |
Top Sells
| 1 |
Bristol-Myers Squibb
BMY
|
+$355M |
| 2 |
Royalty Pharma
RPRX
|
+$334M |
| 3 |
McDonald's
MCD
|
+$198M |
| 4 |
Union Pacific
UNP
|
+$188M |
| 5 |
HES
Hess
HES
|
+$182M |
Sector Composition
| 1 | Technology | 26.31% |
| 2 | Healthcare | 15% |
| 3 | Financials | 12.57% |
| 4 | Consumer Discretionary | 9.55% |
| 5 | Industrials | 8.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
326
PTC Therapeutics
PTCT
$4.52B
| $30.3M | 0.06% |
595,000
+288,244
| +94% | +$14.7M |
|
327
Agilent Technologies
A
$36.3B
| $30.1M | 0.06% |
257,278
+38,784
| +18% | +$4.54M |
|
328
W.W. Grainger
GWW
$47.7B
| $30.1M | 0.06% |
+30,442
| New | +$30.1M |
|
329
KeyCorp
KEY
$21B
| $29.7M | 0.06% |
1,859,069
+2,900
| +0.2% | +$46.4K |
|
330
Broadridge
BR
$29.7B
| $29.6M | 0.05% |
121,900
+34,200
| +39% | +$8.29M |
|
331
Tractor Supply
TSCO
$31.3B
| $29.5M | 0.05% |
535,000
+163,400
| +44% | +$9M |
|
332
Gartner
IT
$18.7B
| $29.4M | 0.05% |
70,100
-2,000
| -3% | -$839K |
|
333
Truist Financial
TFC
$58.4B
| $29.3M | 0.05% |
710,964
-254,300
| -26% | -$10.5M |
|
334
Camden Property Trust
CPT
$11.9B
| $29.2M | 0.05% |
239,000
+189,300
| +381% | +$23.2M |
|
335
lululemon athletica
LULU
$19.6B
| $29M | 0.05% |
102,300
-23,200
| -18% | -$6.57M |
|
336
Aptiv
APTV
$17.9B
| $28.8M | 0.05% |
484,400
+264,800
| +121% | +$15.8M |
|
337
Aura Biosciences
AURA
$402M
| $28.6M | 0.05% |
4,881,125
| – | – |
|
|
EVRI
338
DELISTED
Everi Holdings
EVRI
| $28.5M | 0.05% |
2,087,521
-126,698
| -6% | -$1.73M |
|
339
DuPont de Nemours
DD
$32.6B
| $28.5M | 0.05% |
381,501
+81,000
| +27% | +$6.05M |
|
340
Nuvalent
NUVL
$5.76B
| $28.2M | 0.05% |
397,000
-283,000
| -42% | -$20.1M |
|
341
Delta Air Lines
DAL
$39.6B
| $28.1M | 0.05% |
645,611
-2,408,674
| -79% | -$105M |
|
342
Sanofi
SNY
$116B
| $28M | 0.05% |
504,671
+24,255
| +5% | +$1.35M |
|
343
Equity Residential
EQR
$25.4B
| $27.7M | 0.05% |
386,933
+300,051
| +345% | +$21.5M |
|
344
Astera Labs
ALAB
$35.7B
| $27.7M | 0.05% |
463,932
+412,500
| +802% | +$24.6M |
|
345
Williams Companies
WMB
$69.4B
| $27.6M | 0.05% |
+462,499
| New | +$27.6M |
|
346
Travelers Companies
TRV
$61.8B
| $27.5M | 0.05% |
103,913
-16,200
| -13% | -$4.28M |
|
347
Iron Mountain
IRM
$27.3B
| $27.4M | 0.05% |
318,052
+203,900
| +179% | +$17.5M |
|
348
Apogee Therapeutics
APGE
$2.29B
| $27.2M | 0.05% |
727,000
+486,800
| +203% | +$18.2M |
|
349
Zevra Therapeutics
ZVRA
$468M
| $27.1M | 0.05% |
3,618,000
-32,000
| -0.9% | -$240K |
|
350
Avery Dennison
AVY
$13B
| $27.1M | 0.05% |
152,136
-51,540
| -25% | -$9.17M |
|